COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

13/12/2024 - 18:23

PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing the [...]

Protest as MPPs come to Stratford on pre-budget tour: Local citizens angry at Ford government for underfunding, privatizing & destroying our public health care plan to make their voices heard

13/12/2024 - 19:38

Attn: Assignment Editor STRATFORD, Ontario, Dec. 13, 2024 (GLOBE NEWSWIRE) -- As the government travels to Stratford to hold Pre-Budget Hearings, concerned citizens from Stratford and area will gather to send a message [...]

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

13/12/2024 - 13:18

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the Phase 3 ATTRibute-CM study; final approval decision, typically consistent [...]

At EuroEcho, Ebit (Esaote Group) presents the world premiere of ZEfiRO, the new “cloud-native” PACS for the SUITESTENSA platform, redefining its design philosophy

13/12/2024 - 13:25

With its adoption of “zero-footprint” technology, ZEfiRO guarantees clinician and operators immediacy and usability in reading images wherever they are, with a positive impact on the management of diagnosis and [...]

Dentsply Sirona Declares Quarterly Cash Dividend

13/12/2024 - 13:30

CHARLOTTE, N.C., Dec. 13, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of [...]

Incyclix Bio Announces Interim Clinical Data from the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

13/12/2024 - 13:30

INX-315 was safe and well tolerated in monotherapy dose escalation INX-315 monotherapy demonstrated antitumor activity in heavily pretreated patients with ER+/HER2- breast cancer and CCNE1-amplified ovarian cancer [...]

BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

13/12/2024 - 13:50

BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer patients treated with Bria [...]

iTeos Therapeutics présente les données intermédiaires de l’essai clinique A2A-005, ainsi que les données translationnelles et précliniques relatives à l’inupadénant lors du congrès d’immuno-oncologie de l’ESMO

13/12/2024 - 13:55

- L’essai de phase 2 A2A-005 portant sur l’inupadénant + carboplatine/pémétrexed a démontré un taux de réponse globale (TRG) de 63,9 % et une SSP médiane de 7,7 mois pour tous les patients évaluables sur l’ensemble des [...]

Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

13/12/2024 - 14:00

Same-day dosing results comparable to next day dosing schedules LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with [...]

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13/12/2024 - 14:00

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]

Sienna Announces December Dividend

13/12/2024 - 14:30

MARKHAM, Ontario, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

13/12/2024 - 14:30

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse model of triple [...]

QHSLab (OTCQB:USAQ) and South Dakota State University Celebrate NSF Invitation to Submit STTR Application for AIR-GUIDDE Technology

13/12/2024 - 14:30

NSF Recognition: A Testament to Innovation Driving Strategic Growth and Shareholder Value WEST PALM BEACH, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- QHSLab Inc. ("the Company") (OTCQB: USAQ) , a leading provider of digital [...]

Amarin Appoints Peter Fishman Chief Financial Officer

13/12/2024 - 15:00

Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today [...]

PharmAla Announces Private Placement

13/12/2024 - 15:25

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card

13/12/2024 - 15:46

Vote “ FOR ” All Four Kellner Group Nominees for Urgently Needed Change Incumbent Board has Destroyed Stockholder Value and Imperiled AIM’s Future through Breaches of Fiduciary Duty and Bad Faith Actions Stock Price has [...]

SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List

13/12/2024 - 16:00

CLEVELAND, Dec. 13, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics has been named to the Crain’s Cleveland Business Fast 50, placing first on the list of rapidly growing, privately held companies ranked by revenue growth [...]

ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference

13/12/2024 - 11:00

Garching / Munich, Germany, December 13, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew Cavey and Chief [...]

La formulation sous-cutanée de DARZALEX® (daratumumab) démontre une réduction de 51 pour cent du risque de progression vers un myélome multiple actif chez des patients atteints d’un myélome multiple indolent à haut risque

13/12/2024 - 11:38

Le premier traitement sous-cutané anti-CD38 à démontrer un potentiel de prévention des lésions au niveau des organes cibles et de prolongation de la survie sans progression et de la survie globale, d’après les résultats [...]